Listed

Filana Therapeutics, Inc.

FLNANasdaqCIK 1069530HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$11.2m, Q1 FY2026
Net income−$10.3m, Q1 FY2026
Filana Therapeutics, Inc., income statement, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m25.0Research and development, Q2 FY2023, three months to 2023-06-30$25.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure23.6Research and development, Q3 FY2023, three months to 2023-09-30$23.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure18.7Research and development, Q4 FY2023, three months to 2023-12-31$18.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure16.2Research and development, Q1 FY2024, three months to 2024-03-31$16.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure15.2Research and development, Q2 FY2024, three months to 2024-06-30$15.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure17.7Research and development, Q3 FY2024, three months to 2024-09-30$17.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure20.5Research and development, Q4 FY2024, three months to 2024-12-31$20.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure13.7Research and development, Q1 FY2025, three months to 2025-03-31$13.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure5.1Research and development, Q2 FY2025, three months to 2025-06-30$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure4.0Research and development, Q3 FY2025, three months to 2025-09-30$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure3.9Research and development, Q4 FY2025, three months to 2025-12-31$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure4.5Research and development, Q1 FY2026, three months to 2026-03-31$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Operating income$m(28.8)Operating income, Q2 FY2023, three months to 2023-06-30−$28.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure(27.9)Operating income, Q3 FY2023, three months to 2023-09-30−$27.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure(22.8)Operating income, Q4 FY2023, three months to 2023-12-31−$22.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(19.9)Operating income, Q1 FY2024, three months to 2024-03-31−$19.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure(61.4)Operating income, Q2 FY2024, three months to 2024-06-30−$61.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(30.6)Operating income, Q3 FY2024, three months to 2024-09-30−$30.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(29.5)Operating income, Q4 FY2024, three months to 2024-12-31−$29.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(24.6)Operating income, Q1 FY2025, three months to 2025-03-31−$24.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure(45.4)Operating income, Q2 FY2025, three months to 2025-06-30−$45.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(11.9)Operating income, Q3 FY2025, three months to 2025-09-30−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(13.6)Operating income, Q4 FY2025, three months to 2025-12-31−$13.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(11.2)Operating income, Q1 FY2026, three months to 2026-03-31−$11.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Income tax$m0.0Income tax, Q2 FY2023, three months to 2023-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figurenot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-03, accession 0001437749-25-005919. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Net income$m(26.4)Net income, Q2 FY2023, three months to 2023-06-30−$26.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure(25.7)Net income, Q3 FY2023, three months to 2023-09-30−$25.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure(20.9)Net income, Q4 FY2023, three months to 2023-12-31−$20.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure25.0Net income, Q1 FY2024, three months to 2024-03-31$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure6.2Net income, Q2 FY2024, three months to 2024-06-30$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(27.9)Net income, Q3 FY2024, three months to 2024-09-30−$27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(27.6)Net income, Q4 FY2024, three months to 2024-12-31−$27.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(23.4)Net income, Q1 FY2025, three months to 2025-03-31−$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure(44.2)Net income, Q2 FY2025, three months to 2025-06-30−$44.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(10.8)Net income, Q3 FY2025, three months to 2025-09-30−$10.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure(12.5)Net income, Q4 FY2025, three months to 2025-12-31−$12.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(10.3)Net income, Q1 FY2026, three months to 2026-03-31−$10.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Diluted EPS$ per share(0.63)Diluted EPS, Q2 FY2023, three months to 2023-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure(0.61)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figurenot reported(0.43)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure0.13Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(0.58)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figurenot reported(0.48)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure(0.92)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(0.22)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figurenot reportednot reported
Basic EPS$ per share(0.63)Basic EPS, Q2 FY2023, three months to 2023-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure(0.61)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figurenot reported0.58Basic EPS, Q1 FY2024, three months to 2024-03-31$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure0.13Basic EPS, Q2 FY2024, three months to 2024-06-30$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(0.58)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figurenot reported(0.48)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure(0.92)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure(0.22)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figurenot reported(0.21)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure

Balance sheet

Cash and equivalents$86.6m, Q1 FY2026
Shareholders' equity$68.1m, Q1 FY2026
Filana Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31
Cash and equivalents$m168Cash and equivalents, Q2 FY2023, at 2023-06-30$168.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure142Cash and equivalents, Q3 FY2023, at 2023-09-30$142.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure121Cash and equivalents, FY2023, at 2023-12-31$121.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-03, accession 0001437749-25-005919.Report this figure124Cash and equivalents, Q1 FY2024, at 2024-03-31$124.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001437749-24-016040.Report this figure207Cash and equivalents, Q2 FY2024, at 2024-06-30$207.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure149Cash and equivalents, Q3 FY2024, at 2024-09-30$149.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure129Cash and equivalents, FY2024, at 2024-12-31$128.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure117Cash and equivalents, Q1 FY2025, at 2025-03-31$117.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure112Cash and equivalents, Q2 FY2025, at 2025-06-30$112.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure106Cash and equivalents, Q3 FY2025, at 2025-09-30$106.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure95.5Cash and equivalents, FY2025, at 2025-12-31$95.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure86.6Cash and equivalents, Q1 FY2026, at 2026-03-31$86.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Current assets$m175Current assets, Q2 FY2023, at 2023-06-30$174.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure150Current assets, Q3 FY2023, at 2023-09-30$150.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001437749-23-030502.Report this figure130Current assets, FY2023, at 2023-12-31$129.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-03, accession 0001437749-25-005919.Report this figure134Current assets, Q1 FY2024, at 2024-03-31$134.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001437749-24-016040.Report this figure222Current assets, Q2 FY2024, at 2024-06-30$222.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure203Current assets, Q3 FY2024, at 2024-09-30$202.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure137Current assets, FY2024, at 2024-12-31$136.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure120Current assets, Q1 FY2025, at 2025-03-31$120.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure115Current assets, Q2 FY2025, at 2025-06-30$114.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure109Current assets, Q3 FY2025, at 2025-09-30$108.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure97.7Current assets, FY2025, at 2025-12-31$97.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure88.0Current assets, Q1 FY2026, at 2026-03-31$88.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Total assets$m197Total assets, Q2 FY2023, at 2023-06-30$197.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure173Total assets, Q3 FY2023, at 2023-09-30$172.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001437749-23-030502.Report this figure152Total assets, FY2023, at 2023-12-31$151.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-03, accession 0001437749-25-005919.Report this figure156Total assets, Q1 FY2024, at 2024-03-31$155.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001437749-24-016040.Report this figure244Total assets, Q2 FY2024, at 2024-06-30$243.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure224Total assets, Q3 FY2024, at 2024-09-30$223.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure158Total assets, FY2024, at 2024-12-31$157.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure141Total assets, Q1 FY2025, at 2025-03-31$140.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure135Total assets, Q2 FY2025, at 2025-06-30$135.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure130Total assets, Q3 FY2025, at 2025-09-30$129.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure118Total assets, FY2025, at 2025-12-31$118.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure108Total assets, Q1 FY2026, at 2026-03-31$108.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Current liabilities$m17.9Current liabilities, Q2 FY2023, at 2023-06-30$17.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure17.4Current liabilities, Q3 FY2023, at 2023-09-30$17.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001437749-23-030502.Report this figure14.2Current liabilities, FY2023, at 2023-12-31$14.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-03, accession 0001437749-25-005919.Report this figure77.1Current liabilities, Q1 FY2024, at 2024-03-31$77.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001437749-24-016040.Report this figure54.6Current liabilities, Q2 FY2024, at 2024-06-30$54.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure57.0Current liabilities, Q3 FY2024, at 2024-09-30$57.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure11.8Current liabilities, FY2024, at 2024-12-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure13.2Current liabilities, Q1 FY2025, at 2025-03-31$13.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure47.3Current liabilities, Q2 FY2025, at 2025-06-30$47.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure48.0Current liabilities, Q3 FY2025, at 2025-09-30$48.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure43.8Current liabilities, FY2025, at 2025-12-31$43.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure40.1Current liabilities, Q1 FY2026, at 2026-03-31$40.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Total liabilities$m17.9Total liabilities, Q2 FY2023, at 2023-06-30$17.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure17.4Total liabilities, Q3 FY2023, at 2023-09-30$17.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0001437749-23-030502.Report this figure14.2Total liabilities, FY2023, at 2023-12-31$14.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-03, accession 0001437749-25-005919.Report this figurenot reportednot reported57.1Total liabilities, Q3 FY2024, at 2024-09-30$57.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure11.8Total liabilities, FY2024, at 2024-12-31$11.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure13.3Total liabilities, Q1 FY2025, at 2025-03-31$13.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure47.4Total liabilities, Q2 FY2025, at 2025-06-30$47.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure48.2Total liabilities, Q3 FY2025, at 2025-09-30$48.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure44.0Total liabilities, FY2025, at 2025-12-31$44.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure40.2Total liabilities, Q1 FY2026, at 2026-03-31$40.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Shareholders' equity$m179Shareholders' equity, Q2 FY2023, at 2023-06-30$179.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure155Shareholders' equity, Q3 FY2023, at 2023-09-30$155.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure137Shareholders' equity, FY2023, at 2023-12-31$137.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-12, accession 0001437749-26-007962.Report this figure78.6Shareholders' equity, Q1 FY2024, at 2024-03-31$78.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure189Shareholders' equity, Q2 FY2024, at 2024-06-30$189.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure167Shareholders' equity, Q3 FY2024, at 2024-09-30$166.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure146Shareholders' equity, FY2024, at 2024-12-31$145.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure128Shareholders' equity, Q1 FY2025, at 2025-03-31$127.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure88.0Shareholders' equity, Q2 FY2025, at 2025-06-30$88.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure81.6Shareholders' equity, Q3 FY2025, at 2025-09-30$81.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure74.4Shareholders' equity, FY2025, at 2025-12-31$74.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure68.1Shareholders' equity, Q1 FY2026, at 2026-03-31$68.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure

Cash flow

Operating cash flow−$8.9m, Q1 FY2026
Capital expenditure$501.0k, Q4 FY2025
Filana Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31
Operating cash flow$m(19.9)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-08, accession 0001437749-24-025611. Derived: 6-month figure less the 3-month figure.Report this figure(26.5)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$26.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001437749-24-033944. Derived: 9-month figure less the 6-month figure.Report this figure(22.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$22.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(19.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$19.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure(18.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$18.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001437749-25-026686. Derived: 6-month figure less the 3-month figure.Report this figure(18.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$18.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001437749-25-034427. Derived: 9-month figure less the 6-month figure.Report this figure(61.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$61.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(11.3)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$11.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure(4.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001437749-25-026686. Derived: 6-month figure less the 3-month figure.Report this figure(6.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001437749-25-034427. Derived: 9-month figure less the 6-month figure.Report this figure(9.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure(8.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure
Capital expenditure$m(0.0)Capital expenditure, Q2 FY2023, three months to 2023-06-30−$6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-08-08, accession 0001437749-24-025611. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$22.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001437749-24-033944. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$41.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$29.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001437749-25-026686. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001437749-25-034427. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$57.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001437749-25-026686. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001437749-25-034427. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2025, three months to 2025-12-31$501.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001437749-26-007962. Derived: 12-month figure less the 9-month figure.Report this figurenot reported

Shares

Diluted shares (weighted)48.31m, Q3 FY2025
Filana Therapeutics, Inc., shares, quarterly
Line itemUnitQ1 FY20132013-03-31Q1 FY20222022-03-31Q2 FY20222022-06-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30
Diluted shares (weighted)m shares44.9Diluted shares (weighted), Q1 FY2013, three months to 2013-03-3144,932,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2013-04-24, accession 0001193125-13-170549.Report this figure40.0Diluted shares (weighted), Q1 FY2022, three months to 2022-03-3139,962,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-01, accession 0001069530-23-000017.Report this figure40.0Diluted shares (weighted), Q2 FY2022, three months to 2022-06-3040,015,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-03, accession 0001069530-23-000039.Report this figure41.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3141,739,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001437749-24-016040.Report this figure41.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3041,793,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001437749-24-025611.Report this figure42.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3042,002,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001437749-24-033944.Report this figure44.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3144,102,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure46.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3046,202,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure48.0Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3047,976,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure48.3Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3148,262,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001437749-25-015478.Report this figure48.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3048,308,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001437749-25-026686.Report this figure48.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3048,308,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001437749-25-034427.Report this figure

Shares outstanding: 48.31mShares outstanding, period not labelled, at 2026-05-0448,307,896 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-05-07, accession 0001437749-26-015664.Report this figure at May 4, 2026, from the cover of the 10-Q filed May 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. Listed shows no prices and gives no investment advice.